Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expressing Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02276300
What this trial is testing

HER2-Peptide Vaccination of Patients With Solid Tumors

Who this might be right for
Gastric CancerBreast Cancer
Technical University of Munich 2
Testing effectiveness (Phase 2)UnknownNCT05912205
What this trial is testing

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Who this might be right for
Urothelial Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Not applicableUnknownNCT06857747
What this trial is testing

Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

Who this might be right for
Breast Cancer
QIAO LI 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07150208
What this trial is testing

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-low Expressing Breast Cancer
Fudan University 140
Not applicableLooking for participantsNCT05945732
What this trial is testing

DESTINY Breast Respond HER2-(Ultra)Low Europe

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 2,295
Early research (Phase 1)Active Not RecruitingNCT00902044
What this trial is testing

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Who this might be right for
Sarcoma
Baylor College of Medicine 36
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Testing effectiveness (Phase 2)Looking for participantsNCT06026657
What this trial is testing

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Margaret Gatti-Mays 42
Testing effectiveness (Phase 2)Study completedNCT01730612
What this trial is testing

ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

Who this might be right for
HER2 Negative Breast Carcinoma Expressing CEA
Nantes University Hospital 23
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Early research (Phase 1)Not Yet RecruitingNCT07036185
What this trial is testing

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Who this might be right for
Gastric/Gastroesophageal Junction CancerBreast CancerColorectal Cancer+3 more
Shanghai Bao Pharmaceuticals Co., Ltd. 66
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477
Testing effectiveness (Phase 2)Looking for participantsNCT06015048
What this trial is testing

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Who this might be right for
HER2-expressing Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 364
Early research (Phase 1)Study completedNCT00291473
What this trial is testing

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Who this might be right for
Esophageal CancerLung CancerStomach Cancer+2 more
Ludwig Institute for Cancer Research 9
Large-scale testing (Phase 3)Study completedNCT03130790
What this trial is testing

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

Who this might be right for
Gastric Cancer
ASLAN Pharmaceuticals 52
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)Looking for participantsNCT05302284
What this trial is testing

RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaHER2-expressing
RemeGen Co., Ltd. 452
Testing effectiveness (Phase 2)Active Not RecruitingNCT05625087
What this trial is testing

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Who this might be right for
Breast Cancer Stage IV
UNICANCER 162
Early research (Phase 1)Study completedNCT06710990
What this trial is testing

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 17
Next Page